These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12888267)

  • 1. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component.
    Peters KG; Davis MG; Howard BW; Pokross M; Rastogi V; Diven C; Greis KD; Eby-Wilkens E; Maier M; Evdokimov A; Soper S; Genbauffe F
    J Inorg Biochem; 2003 Aug; 96(2-3):321-30. PubMed ID: 12888267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of protein tyrosine phosphatase 1B and alkaline phosphatase by bis(maltolato)oxovanadium (IV).
    Li M; Ding W; Baruah B; Crans DC; Wang R
    J Inorg Biochem; 2008 Oct; 102(10):1846-53. PubMed ID: 18728000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats.
    Winter CL; Lange JS; Davis MG; Gerwe GS; Downs TR; Peters KG; Kasibhatla B
    Exp Biol Med (Maywood); 2005 Mar; 230(3):207-16. PubMed ID: 15734724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of insulin-like growth factor type 1 receptor and protein kinase Cdelta in bis(maltolato)oxovanadium(IV)-induced phosphorylation of protein kinase B in HepG2 cells.
    Mehdi MZ; Vardatsikos G; Pandey SK; Srivastava AK
    Biochemistry; 2006 Sep; 45(38):11605-15. PubMed ID: 16981720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.
    Liboiron BD; Thompson KH; Hanson GR; Lam E; Aebischer N; Orvig C
    J Am Chem Soc; 2005 Apr; 127(14):5104-15. PubMed ID: 15810845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bis(maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo.
    Mohammad A; Wang J; McNeill JH
    Mol Cell Biochem; 2002 Jan; 229(1-2):125-8. PubMed ID: 11936837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin.
    Bordbar AK; Creagh AL; Mohammadi F; Haynes CA; Orvig C
    J Inorg Biochem; 2009 Apr; 103(4):643-7. PubMed ID: 19056126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanism of bis(maltolato)oxovanadium(IV)-induced insulin signaling in 3T3-L1 and IM9 cells: impact of dexamethasone.
    Bose S; Farah MA; Jung HC; Lee JH; Kim Y
    J Mol Endocrinol; 2007 Jun; 38(6):627-49. PubMed ID: 17556533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of vanadium on insulin sensitivity and appetite.
    Wang J; Yuen VG; McNeill JH
    Metabolism; 2001 Jun; 50(6):667-73. PubMed ID: 11398143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotransformation of BMOV in the presence of blood serum proteins.
    Sanna D; Bíró L; Buglyó P; Micera G; Garribba E
    Metallomics; 2012 Jan; 4(1):33-6. PubMed ID: 22094980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
    Yuen VG; Orvig C; McNeill JH
    Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-diabetic bis(maltolato)oxovanadium(IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains.
    Winter PW; Al-Qatati A; Wolf-Ringwall AL; Schoeberl S; Chatterjee PB; Barisas BG; Roess DA; Crans DC
    Dalton Trans; 2012 Jun; 41(21):6419-30. PubMed ID: 22569684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV).
    Yuen VG; Orvig C; McNeill JH
    Can J Physiol Pharmacol; 1993; 71(3-4):263-9. PubMed ID: 8402390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo.
    Marzban L; Rahimian R; Brownsey RW; McNeill JH
    Endocrinology; 2002 Dec; 143(12):4636-45. PubMed ID: 12446591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bis(maltolato)-oxovanadium (IV)-induced phosphorylation of PKB, GSK-3 and FOXO1 contributes to its glucoregulatory responses (review).
    Vardatsikos G; Mehdi MZ; Srivastava AK
    Int J Mol Med; 2009 Sep; 24(3):303-9. PubMed ID: 19639221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Speciation studies of vanadium in human liver (HepG2) cells after in vitro exposure to bis(maltolato)oxovanadium(IV) using HPLC online with elemental and molecular mass spectrometry.
    Nischwitz V; Davies JT; Marshall D; González M; Gómez Ariza JL; Goenaga-Infante H
    Metallomics; 2013 Dec; 5(12):1685-97. PubMed ID: 24136403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes.
    Thompson KH; Chiles J; Yuen VG; Tse J; McNeill JH; Orvig C
    J Inorg Biochem; 2004 May; 98(5):683-90. PubMed ID: 15134913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV).
    Willsky GR; Goldfine AB; Kostyniak PJ; McNeill JH; Yang LQ; Khan HR; Crans DC
    J Inorg Biochem; 2001 May; 85(1):33-42. PubMed ID: 11377693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of decavanadate and insulin enhancing vanadium compounds on glucose uptake in isolated rat adipocytes.
    Pereira MJ; Carvalho E; Eriksson JW; Crans DC; Aureliano M
    J Inorg Biochem; 2009 Dec; 103(12):1687-92. PubMed ID: 19850351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease.
    Carr AN; Davis MG; Eby-Wilkens E; Howard BW; Towne BA; Dufresne TE; Peters KG
    Am J Physiol Heart Circ Physiol; 2004 Jul; 287(1):H268-76. PubMed ID: 14988069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.